{"id":"NCT02058563","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older","officialTitle":"Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Seven Years and Older (209762)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-07-01","primaryCompletion":"2015-05-24","completion":"2015-09-17","firstPosted":"2014-02-10","resultsPosted":"2017-04-10","lastUpdate":"2018-06-06"},"enrollment":996,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Rubella","Mumps","Measles"],"interventions":[{"type":"BIOLOGICAL","name":"Priorix速","otherNames":[]},{"type":"BIOLOGICAL","name":"Merck's M-M-R速II, Measles, Mumps, and Rubella Virus Vaccine","otherNames":[]}],"arms":[{"label":"INV_MMR Group","type":"EXPERIMENTAL"},{"label":"COM_MMR Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the immunogenicity and safety of GSK's trivalent MMR (Priorix速), comparing it to Merck\"s MMR vaccine (M-M-R速II), which is approved for use in the US.","primaryOutcome":{"measure":"Anti-measles Virus Antibody Concentrations.","timeFrame":"At Day 42","effectByArm":[{"arm":"INV_MMR Group","deltaMin":1795.6,"sd":null},{"arm":"COM_MMR Group","deltaMin":1783.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":8,"exclusionCount":11},"locations":{"siteCount":17,"countries":["United States","Estonia","Slovakia"]},"refs":{"pmids":["29902133"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":454},"commonTop":["Injection site erythema","Vaccination site pain","Injection site swelling","Pyrexia"]}}